Peptides for Male Fertility: What the Evidence Shows

Male infertility shows up in roughly half of couples who can't conceive, and a big share of those cases trace back to problems with sperm production. A small group of peptide hormones, led by human chorionic gonadotropin (hCG) and follicle-stimulating hormone (FSH), can restart or protect sperm production in specific men, and a handful of newer peptides like kisspeptin are being studied for the same job. This review walks through what each peptide does, how strong the evidence actually is, and where the marketing runs far ahead of the science.

How Male Fertility Hormones Actually Work

Sperm production is controlled by a chain of signals that starts in the brain. A region called the hypothalamus releases gonadotropin-releasing hormone (GnRH) in short pulses. GnRH tells the pituitary gland to release two more hormones: luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

LH travels to the Leydig cells in the testicles and tells them to make testosterone. The testosterone made inside the testicle (called intratesticular testosterone) reaches concentrations far higher than what circulates in the blood, and sperm cells need that high local level to mature. FSH acts on a different set of cells, the Sertoli cells, which directly support sperm development.

This chain is the key to understanding fertility peptides. Every fertility peptide is trying to fix a broken link somewhere along this hypothalamus-pituitary-testicle axis. Where the break is determines which peptide can help, and whether any peptide can help at all.

Doctors split the problem into two broad buckets. In secondary hypogonadism (also called hypogonadotropic hypogonadism), the brain or pituitary isn't sending enough signal, so LH and FSH come back low or low-normal on a blood test even though the testicles could work fine if they got the message. In primary hypogonadism, the signal is fine, or even high, but the testicles can't respond, so LH and FSH read high while testosterone and sperm stay low. Peptides are mostly a tool for the first bucket. They replace or amplify a missing signal. They cannot force a damaged testicle to do something it's physically incapable of, which is why the same drug can be a near-cure in one man and useless in another.

A crucial point that trips up a lot of men: regular testosterone replacement therapy (TRT) does the opposite of what you'd expect for fertility. When you inject testosterone, the brain senses plenty of it in the blood and shuts down GnRH, LH, and FSH. Intratesticular testosterone then crashes, and sperm production often stops. Studies report azoospermia (zero sperm in the ejaculate) in roughly 40 percent of men on testosterone therapy. That's why fertility-focused care almost never uses plain testosterone. The damage is usually reversible after stopping, but recovery can take months to more than a year, and a minority of men don't fully bounce back, so it's not a risk to take lightly if children are in the plan.

One more piece of background matters: sperm take time. A full cycle of sperm production runs about 72 to 74 days, and the cells then spend more time maturing and being transported. So any fertility peptide that works does so on a delay. A semen analysis at week 4 means almost nothing. The honest timeline for judging whether a peptide is working is three to six months at a minimum, and full results in hypogonadotropic hypogonadism can take one to two years. Patience is part of the protocol, not a side issue.

The Peptides at a Glance

The table below sorts the main peptides by how strong the human evidence is. "Peptide" is used loosely here, since hCG and FSH are technically glycoprotein hormones, but they're the workhorses of fertility medicine and belong in any honest review.

Peptide	What it does	Best evidence for	Evidence grade
hCG (human chorionic gonadotropin)	Mimics LH, drives Leydig cells to make intratesticular testosterone	Hypogonadotropic hypogonadism; preserving fertility on TRT	Strong (guideline grade A for HH)
FSH (urinary or recombinant)	Stimulates Sertoli cells to support sperm maturation	Combined with hCG for HH; selected idiopathic cases	Strong for HH; mixed for idiopathic infertility
GnRH (pulsatile pump)	Replaces the brain's natural pulse signal	Congenital hypogonadotropic hypogonadism	Moderate to strong, but niche
Kisspeptin (kisspeptin-10, KP-54)	Triggers natural GnRH release upstream	Research only; raises LH and testosterone short-term	Early/experimental
Growth hormone secretagogues (sermorelin, ipamorelin, CJC-1295)	Raise GH and IGF-1	No proven fertility benefit	Weak/theoretical

hCG: The Most Proven Fertility Peptide

Human chorionic gonadotropin is the closest thing to a fertility "first-line" peptide. Its shape is similar enough to LH that it binds the same receptors on Leydig cells, so it tells the testicles to make testosterone right where sperm need it. hCG is also FDA-approved for selected cases of hypogonadotropic hypogonadism in males, which sets it apart from most peptides discussed in the wellness world.

Where hCG works best

The strongest use is in men whose brains or pituitaries don't send enough LH and FSH, a condition called hypogonadotropic hypogonadism. In these men, combined therapy with hCG (to replace LH) and FSH restores sperm production in a high share of patients. Reviews of gonadotropin treatment in this group report sperm appearing in the ejaculate in roughly 80 percent of men over 12 to 24 months, with pregnancy rates around 50 percent. Major guidelines treat gonadotropin therapy for hypogonadotropic hypogonadism as a grade A recommendation, the highest tier.

hCG to protect fertility on testosterone therapy

The second well-supported use is preserving sperm production in men who want or need testosterone therapy but also want to stay fertile. Because testosterone alone shuts down the testicles, adding low-dose hCG keeps intratesticular testosterone high. In a clinical series, men on testosterone who added low-dose hCG (around 500 IU every other day) did not become azoospermic, and several couples (9 of 26 men) achieved pregnancy during treatment. This finding underpins the common practice of pairing hCG with TRT for fertility-minded men.

Honest limits

hCG is not a cure-all. In men with primary testicular failure (the testicles themselves are damaged), hCG can raise testosterone but usually can't manufacture sperm that the testicle is incapable of producing. The most common side effect is gynecomastia (breast tissue growth), because hCG drives testosterone, some of which converts to estradiol through the enzyme aromatase. Doctors sometimes add an aromatase inhibitor to manage that.

What treatment actually looks like

In practice, hCG is injected under the skin or into muscle a few times a week. For fertility preservation alongside testosterone, low doses around 500 IU every other day are common. For inducing sperm production in hypogonadotropic hypogonadism, doses are often higher and FSH is layered in after a few months once testosterone has come up. Monitoring is hands-on: blood testosterone and estradiol every several weeks early on, and a semen analysis roughly every two to three months once enough time has passed for new sperm to appear. Two markers help predict success before treatment even starts. A larger baseline testicular volume and a higher baseline inhibin B (a hormone made by Sertoli cells) both point to better odds, while a history of undescended testicles points the other way. This is why a good clinician measures these things first instead of just writing a prescription.

FSH: The Sertoli Cell Partner

FSH does the job hCG can't: it directly supports the Sertoli cells that nurse sperm through maturation. In hypogonadotropic hypogonadism, FSH is usually combined with hCG, and the pairing is what produces those high sperm-recovery rates. FSH comes as recombinant FSH or as urinary-derived preparations like human menopausal gonadotropin (hMG).

The murkier question is whether FSH helps men with so-called idiopathic infertility, meaning low sperm counts with normal LH and FSH levels and no clear cause. Here the evidence is genuinely mixed. Some meta-analyses report improved sperm parameters and higher pregnancy rates after FSH treatment, with spontaneous pregnancy odds several times higher than no treatment. But a well-run randomized trial found no benefit when men were selected only by the loose criteria of idiopathic low sperm count and normal FSH.

The likely explanation is that FSH helps a subgroup of "responders," perhaps defined by specific FSH-receptor genetics, while doing little for everyone else. That's an important nuance: FSH for idiopathic infertility is not a reliable treatment for the average man, and using it without identifying likely responders is closer to a coin flip than a proven therapy.

Beyond raw sperm count, some studies report that FSH improves sperm DNA quality, lowering the fraction of sperm carrying fragmented DNA. That matters because DNA damage can affect fertilization and early embryo health even when the count looks acceptable. It's a plausible benefit and a reasonable reason a specialist might trial FSH in a selected man, but it's still drawn from small studies, and it shouldn't be oversold as settled. The bottom line for FSH outside of hypogonadotropic hypogonadism: real promise in the right patient, weak average results, and a need for careful selection rather than blanket use.

GnRH Pulsatile Therapy: Effective but Niche

GnRH is the brain's master fertility signal, and it only works when delivered in pulses. A continuous dose actually shuts the system down, which is why GnRH agonists are used to suppress hormones in conditions like prostate cancer. To use GnRH for fertility, it has to be given through a small pump that mimics the body's natural pulse every 60 to 120 minutes.

In men with congenital hypogonadotropic hypogonadism, pulsatile GnRH works about as well as combined hCG/FSH for inducing sperm production, and several studies suggest it may work faster. It can even rescue some men who failed standard gonadotropin therapy, with sperm appearing in around 60 percent of those switched to the pump in one report. The catch is practical: pumps are inconvenient, less widely available, and only make sense when the pituitary itself can still respond. For most clinics, combined hCG/FSH remains the default.

Kisspeptin: Promising but Experimental

Kisspeptin sits one step above GnRH in the chain. It's the signal that tells the hypothalamus to release GnRH in the first place. That makes it attractive in theory: instead of overriding the system from below, kisspeptin nudges the body to run its own natural rhythm.

The human data are real but early. In a controlled study, kisspeptin-10 acted as a potent stimulator of LH and increased LH pulse frequency in healthy men. In men with type 2 diabetes and mild low testosterone, kisspeptin-10 raised both LH and testosterone. These findings are biologically exciting because they show kisspeptin can switch on the reproductive axis in living men.

But "raises a hormone for a few hours in a study" is a long way from "treats infertility." There are no large trials showing kisspeptin improves sperm counts or pregnancy rates over time, and it isn't an approved fertility treatment. Any clinic selling kisspeptin as a fertility solution today is selling something that hasn't earned that claim. The honest grade is experimental.

Growth Hormone Secretagogues: Weak Evidence for Fertility

This is where marketing and science part ways hardest. Peptides like sermorelin, ipamorelin, and CJC-1295 raise growth hormone and IGF-1. Some clinics promote them for fertility on the logic that IGF-1 supports cellular growth in reproductive tissue. Research confirms these peptides do raise IGF-1, even in hypogonadal men.

What's missing is any solid human evidence that they improve sperm count, sperm quality, or pregnancy rates. The fertility rationale is mechanistic and indirect, built on theory rather than outcome trials. The long-term safety of these peptides for fertility purposes also isn't well studied. If your goal is conceiving, growth hormone secretagogues should be considered unproven for that purpose, not a recommended path.

Evidence Grading: A Sober Summary

It helps to put the honest grade next to each peptide and the condition it actually fits.

Peptide + situation	What the evidence supports	Strength
hCG + FSH for hypogonadotropic hypogonadism	Restores sperm in ~80% over 1-2 years	Strong (grade A)
hCG to preserve fertility alongside TRT	Prevents azoospermia in most men	Strong
Pulsatile GnRH for congenital HH	Comparable to hCG/FSH, sometimes faster	Moderate-strong, niche
FSH for idiopathic infertility	Helps a responder subgroup only	Mixed/inconsistent
Kisspeptin for any fertility goal	Raises LH/testosterone short-term in studies	Experimental
GH secretagogues for fertility	No proven sperm or pregnancy benefit	Weak/theoretical

The pattern is clear. Peptides shine when the problem is a missing brain or pituitary signal and the testicle is healthy. They struggle or fail when the testicle itself is the problem, or when there's no clear hormonal deficiency to correct.

How Fertility Peptides Compare to the Alternatives

Peptides aren't the only fertility tools, and often aren't the first choice. Clomiphene citrate, a pill that blocks estrogen feedback at the brain, raises the body's own LH and FSH and is a common, cheaper option for men with low testosterone and low sperm counts. Aromatase inhibitors like anastrozole can help men with a high estrogen-to-testosterone ratio. Lifestyle factors (weight, heat exposure, smoking, alcohol, certain medications) matter enormously and cost nothing.

For couples who need to conceive on a timeline, assisted reproduction such as IUI or IVF with ICSI can bypass low sperm counts entirely, sometimes more reliably than waiting months for a peptide to work. And surgically correctable problems, like a varicocele or a blockage, won't respond to any peptide at all. A proper workup comes first, peptides second.

Safety, Side Effects, and Red Flags

The injectable gonadotropins (hCG, FSH) are generally well tolerated under medical supervision. The most common issues:

Gynecomastia and high estradiol from hCG, manageable with dose adjustment or an aromatase inhibitor.
Injection-site reactions, acne, and mood changes.
Cost and commitment, since fertility induction can take many months.

The bigger safety problem in 2026 is the gray market. Many peptides sold online are labeled "for research use only," are not FDA-approved drugs, and may be impure, underdosed, or contaminated. Kisspeptin and growth hormone secretagogues in particular are widely sold this way. Buying injectables off a research-chemical site and self-dosing for fertility is risky and unproven.

Red flags worth walking away from: a clinic that prescribes plain testosterone to a man who wants kids, anyone promising kisspeptin or GH peptides will "fix" infertility, and vendors who can't show third-party testing. A reproductive urologist or endocrinologist should run a semen analysis and hormone panel before any peptide enters the picture.

Who These Peptides Are Actually For

hCG with or without FSH is a genuinely good fit for men with hypogonadotropic hypogonadism, and for men who need testosterone therapy but want to protect fertility. Pulsatile GnRH is a strong option for congenital cases at centers that offer it. FSH may help a subset of men with idiopathic low counts, ideally identified before treatment rather than by trial and error.

These peptides are not for men with untreated varicoceles, blockages, primary testicular failure, or no diagnosed hormonal problem. And kisspeptin and growth hormone peptides aren't ready for anyone whose goal is a baby, no matter how the marketing reads. The right move is a full fertility workup first, then matching the specific broken link to the specific peptide that fixes it.

For deeper background, see our PT-141 (bremelanotide) research review, the kisspeptin-10 research review, our comparison of peptide therapy versus TRT, the growth hormone peptides guide, and where to buy peptides legally in 2026.

Frequently Asked Questions

Can hCG actually restore fertility in men?

Yes, in the right men. hCG mimics LH and raises intratesticular testosterone, and in men with hypogonadotropic hypogonadism it restores sperm production in a high percentage of cases, especially when combined with FSH. It also prevents the loss of sperm production in men on testosterone therapy. It does not work well for men whose testicles themselves are damaged.

Why is regular testosterone bad for fertility?

Injected testosterone signals the brain that levels are high, so the brain stops releasing LH and FSH. Without LH, intratesticular testosterone collapses, and without that high local level sperm stop maturing. Studies report no sperm in the ejaculate in roughly 40 percent of men on testosterone therapy. That's why fertility-focused doctors use hCG, clomiphene, or gonadotropins instead.

Does kisspeptin work for male infertility?

Not yet in any proven way. Kisspeptin can switch on the reproductive axis and raise LH and testosterone for hours in research studies, which is genuinely promising. But there are no large trials showing it improves sperm counts or pregnancy rates over time, and it isn't an approved fertility treatment. Treat current kisspeptin fertility claims as experimental.

Do growth hormone peptides like ipamorelin improve sperm?

There's no good human evidence that they do. Sermorelin, ipamorelin, and CJC-1295 reliably raise IGF-1, and the fertility argument is built on that mechanism rather than on actual sperm or pregnancy outcomes. For conceiving, they should be considered unproven, not a recommended treatment.

Are fertility peptides FDA-approved?

Some are. hCG is FDA-approved for selected cases of hypogonadotropic hypogonadism in males. FSH preparations are approved drugs used in fertility care. Kisspeptin and growth hormone secretagogues are not FDA-approved fertility treatments and are often sold as research chemicals, which carries real quality and safety risks.

This article is for educational purposes only and is not medical advice. Talk to a reproductive urologist or endocrinologist before starting any fertility treatment.